Corcept Investor Sues Over High Cortisol Drug’s FDA Rejection

Corcept Therapeutics Inc. overhyped its Cushing’s syndrome drug’s application to investors before announcing regulators declined to approve it, a proposed class action said.

The pharmaceutical company misrepresented that its new drug application for relacorilant, which aimed to treat high blood pressure in patients with hypercortisolism, was backed by “powerful evidence,” a pension fund told the US District Court for the Northern District of California.

In reality, the US Food and Drug Administration “had repeatedly raised concerns about the adequacy of the clinical evidence supporting the NDA and, as a result, there was a known material risk that Corcept’s relacorilant NDA ...